bedaquiline fumarate - Profile

What are the generic drug sources for bedaquiline fumarate and what is the scope of freedom to operate?

Bedaquiline fumarate is the generic ingredient in one branded drug marketed by Janssen Therap and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bedaquiline fumarate has ninety-seven patent family members in thirty-nine countries.

Summary for bedaquiline fumarate

International Patents:	97
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bedaquiline fumarate

Constraining patent/regulatory exclusivity:

REVISIONS TO THE LABELING TO REFLECT THE RESULTS OF A CLINICAL STUDY TO FULFILL POST MARKETING REQUIREMENT 1988-001

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for bedaquiline fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-002	May 27, 2020		RX	Yes	No	8,546,428		Y	Y
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-002	May 27, 2020		RX	Yes	No	7,498,343		Y	Y
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-002	May 27, 2020		RX	Yes	No
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-002	May 27, 2020		RX	Yes	No
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-002	May 27, 2020		RX	Yes	No
Janssen Therap	SIRTURO	bedaquiline fumarate	TABLET;ORAL	204384-001	Dec 28, 2012		RX	Yes	Yes	7,498,343		Y	Y

International Patents for bedaquiline fumarate

Country	Patent Number	Title	Estimated Expiration
Brazil	0312927	Derivados de quinolina e seu uso como inibidores micobacterias
Montenegro	P9208	DERIVATI HINOLINA I NJIHOVA UPOTREBA KAO MIKOBAKTERIJSKIH INHIBITORA (QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS)
Iceland	7620	Qínólín afleiður og notkun þeirra sem tálma sveppagerla
Portugal	1527050
Canada	2668512
Hungary	S1400047

Supplementary Protection Certificates for bedaquiline fumarate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1527050	178 5021-2014	Slovakia		PRODUCT NAME: BEDACHILIN FUMARAT; REGISTRATION NO/DATE: EU/1/13/901 20140305
1527050	1490050-0	Sweden		PRODUCT NAME: BEDAQUILINE, OR A PHARMACEUTICALLY ACCEPTABLE ACID OR BASE ADDITION SALT THEREOF, INCLUDING BEDAQUILINE FUMARATE; REG. NO/DATE: EU/1/13/901 20140305
1527050	SPC/GB14/057	United Kingdom		PRODUCT NAME: BEDAQUILINE, OR A PHARMACEUTICALLY ACCEPTABLE ACID OR BASE ADDITION SALT THEREOF, INCLUDING BEDAQUILINE FUMARATE; REGISTERED: UK EU/1/13/901 20140307
1527050	C 2014 034	Romania		PRODUCT NAME: BEDAQUILINA SAU O SARE DE ADITIE A UNUI ACID SAU A UNEI BAZEACCEPTABILA FARMACEUTIC A IN-3-IL)-4-(DIMETILAMINO)-2-(NAFTALEN-1-IL)-1-FENILBUTAN-2-OL; NATIONAL AUTHORISATION NUMBER: EU/1/13/901; DATE OF NATIONAL AUTHORISATION: 20140305; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/901; DATE OF FIRST AUTHORISATION IN EEA: 20140305 ACESTEIA, INCLUSIV FUMARAT DE BEDAQUILINA - FUMARAT DE BEDAQUILINA (1R,2S)-1-(6-BROMO-2-METOXIQUINOL
1527050	552	Finland
1527050	122014000083	Germany		PRODUCT NAME: BEDAQUILIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEURE- ODER BASENADDITIONSSALZ DAVON; REGISTRATION NO/DATE: EU/1/13/901 20140305

Investment Scenario, Market Dynamics, and Financial Trajectory for Bedaquiline Fumarate

Last updated: February 3, 2026

Executive Summary

Bedaquiline fumarate (trade name: SIRTURO) is an innovative antimicrobial agent developed for the treatment of multi-drug-resistant tuberculosis (MDR-TB). Approved by the U.S. Food and Drug Administration (FDA) in 2012, it has rapidly gained prominence as a critical component of MDR-TB management in global efforts to curb resistant strains of tuberculosis. This report assesses its investment potential, delves into market dynamics, and projects its financial trajectory through 2030.

Overview of Bedaquiline Fumarate

Attribute	Details
ATC Code	J04AK02
Manufacturer	Johnson & Johnson (Janssen Pharmaceuticals)
Approval Year	2012 (FDA), 2013 (EMA)
Indications	MDR-TB, extensively drug-resistant TB (XDR-TB)
Formulation	Oral, 100 mg tablets
Patents & Exclusivity	Patent expiry anticipated circa 2028; orphan drug status extends market exclusivity in select countries

Investment Scenario

Market Size and Growth Projections

Parameter	2022 Figures	2027 Projection	2030 Projection
Global MDR-TB Market Market Value	~$600 million	~$1.1 billion	~$1.5 billion
Treatment-Eligible Patients (annual)	300,000	370,000	450,000
Bedaquiline Penetration Rate	55%	65%	70%

Source: WHO Global TB Report 2022, IQVIA data (2022)

Key Investment Drivers

• Public Health Commitments: WHO’s end TB strategy aims to reduce TB incidence by 80% by 2030, augmenting demand for novel therapeutics like bedaquiline.
• Patent & Market Exclusivity: Patent nearing expiration (~2028), opening potential for generics, which threaten profit margins but broaden access.
• Pricing & Reimbursement: High-income markets offer premium pricing (~$300–$500 per course), while low-income regions depend on global subsidies and donations.
• Regulatory Landscape: Approvals in over 50 countries but variable access; accelerated pathways in emergent markets.

Risks & Challenges

• Patent Expiry & Generics: Increased risk of biosimilars entering the market post-2028, leading to price erosion.
• Access & Affordability: Limited availability in low-income markets constrains volume growth.
• Resistance Development: Emergence of bedaquiline-resistant strains could impair long-term efficacy.
• Competitive Landscape: Other novel agents (e.g., pretomanid) and combination therapies could diminish market share.

Market Dynamics in Depth

Drivers

1. Global TB Burden & Drug Resistance: WHO reports 10 million incident cases globally in 2021, with approximately 450,000 MDR-TB cases annually, presenting a substantial market for bedaquiline [1].
2. Regulatory Encouragements: Fast-track approvals, inclusion in WHO guidelines (2013+), and Gavi support promote adoption.
3. Combination Therapies: Bedaquiline is often used with linezolid, pretomanid, and other agents, fostering a complex treatment landscape. The successful combination regimens have demonstrated higher success rates.

Barriers & Limitations

• Pricing & Cost-Effectiveness: High costs limit use in low-income settings; ongoing negotiations aim at tiered pricing models.
• Side Effects & Safety Concerns: QT prolongation risks restrict widespread use; monitoring infrastructure remains critical.
• Supply Chain & Manufacturing: Ensuring consistent supply, especially during scaling, remains challenging.

Competitive Landscape

Product	Developer	Status	Notes
Pretomanid	McKinsey & Co (via TB Alliance)	Approved (2020)	Part of BPaL regimen with bedaquiline
Delamanid	Otsuka Pharmaceutical	Approved (2014)	Similar indication; competitive
Linezolid	Various (generic options)	Off-label for MDR-TB	Used off-label with bedaquiline
Clofazimine	Various, generic	Approved	Used as companion drug

Regulatory & Policy Impact

• WHO Recommendations: Bedaquiline integrated into global guidelines since 2013 for MDR-TB.
• National TB Programs: Adoption varies; high burden countries like India, Russia, and China are pivotal markets.

Financial Trajectory Projections (2023–2030)

Revenue Forecasts

Year	Estimated Revenue (USD Millions)	Key Assumptions
2023	$400	Continued adoption, stable pricing
2025	$600	Increased coverage, expanding global access
2027	$850	Market saturation approaches patent expiry; new guidelines expanding use
2028	$900	Slight decline expected post-patent expiry; biosimilar competition emerging
2030	$600	Market stabilization with generic competition

Note: Figures are estimates based on current market growth rates and emerging trends.

Cost & Profit Analysis

Aspect	Estimations
Average Selling Price	$350 per course (high-income countries); tiered pricing in low-income markets
Gross Margin	70–80% in patent-protected phases
R&D Investment	Approx. $200 million over last decade for development and trials
Market Penetration	Estimated 60–70% among eligible MDR-TB cases in high-burden regions

Comparative Analysis with Competing Drugs

Parameter	Bedaquiline	Pretomanid	Delamanid
Approval Year	2012	2020	2014
Regulatory Status	Approved (FDA, EMA, others)	Approved in some markets only	Approved (EMA, some countries)
Cost per Treatment	~$350 in high-income markets	~$400	~$250
Resistance Potential	Emerging concerns	New entrant, less resistance data	Limited data
Side Effect Profile	QT prolongation	QT prolongation, others	QT prolongation, others

Policy & Regulatory Considerations

Policy Area	Impact on Investment & Market Dynamics
Patent Laws	Patent expiry (~2028) opens market for biosimilars, increasing competition
Price Regulation & Reimbursement	Influence profit margins and geographic market penetration
Global Health Initiatives	Gavi, Global Fund support enhances access; creates growth opportunities
Regulatory Harmonization	Streamlines approval processes, accelerates market entry

Deep Dive: Next-Generation & Biosimilar Impact

Post-patent expiration, biosimilars are expected to reduce prices by up to 50%. Industry leaders are preparing for biosimilar rollouts, with some candidates already in late-stage development. This transition will affect revenue streams but may widen access, expanding the overall market.

Conclusion

Bedaquiline fumarate presents substantial opportunities for investors, driven by its critical role in combating MDR-TB globally. While current margins are favorable, patent expiry (~2028) poses significant near-term risks. Market expansion hinges on global health policies, pricing strategies, and resistance management. The transition toward biosimilars will intensify competition and pressure prices but also facilitate broader adoption, especially in resource-limited settings.

---

Key Takeaways

• Market Growth: The global MDR-TB treatment market is projected to nearly double by 2027, with bedaquiline accounting for a significant share.
• Revenue Outlook: High-income markets offer profitable margins pre-2028; post-patent, biosimilar entry will likely suppress prices.
• Investment Risks: Patent expiration, resistance development, and access limitations are primary concerns.
• Strategic Opportunities: Engaging in tiered pricing, expanding access programs, and investing in next-generation formulations may sustain profitability.
• Regulatory Landscape: Continued support from WHO and national policies enhances market stability but requires proactive adaptation to changing regulations.

---

FAQs

1. What is the current patent status of bedaquiline fumarate?

The primary patent protecting bedaquiline is set to expire around 2028. Pending challenges and various formulation patents may influence the precise timing. Post-expiry, biosimilar manufacturers are expected to enter the market.

2. How does resistance impact the future market for bedaquiline?

Emerging resistance threatens the long-term efficacy of bedaquiline, potentially reducing its market share. Monitoring and management are essential, alongside development of combination therapies to mitigate resistance.

3. What are the primary barriers to access in low-income markets?

High treatment costs, weak healthcare infrastructure, lack of diagnostic capabilities, and regulatory hurdles restrict access in resource-limited settings. Global initiatives are attempting to address these issues through subsidies and donation programs.

4. How do biosimilars influence the competitive landscape?

Biosimilars are expected to significantly lower prices post-patent expiry, increasing access but reducing profit per treatment for originator companies. Strategic planning is necessary to maintain market share.

5. Are alternative therapies emerging that could displace bedaquiline?

Yes, agents like pretomanid and novel combination therapies are emerging, which may compete directly. Their adoption depends on regulatory approval, efficacy, safety profile, and cost.

---

References

[1] WHO Global Tuberculosis Report 2022. World Health Organization.
[2] IQVIA. Global Infectious Disease Market Data, 2022.
[3] Johnson & Johnson. SIRTURO Prescribing Information. 2012.
[4] EMA. Bedaquiline approval documentation. 2013.
[5] Gavi. Support initiatives for MDR-TB treatment access, 2022.

Note: All projections and estimations are subject to change based on real-world developments and new data.